Can I Take Saw Palmetto With MOTS-c?

What MOTS-c Actually Does in the Body

MOTS-c is a 16-amino-acid peptide encoded in the 12S ribosomal RNA region of mitochondrial DNA. It activates AMP-activated protein kinase (AMPK), shifts cellular metabolism toward glucose utilization, and translocates to the nucleus to regulate stress-response gene expression. Research published by Lee et al. In Cell Metabolism established that MOTS-c injection improved insulin sensitivity and reduced adiposity in high-fat-fed mice, with AMPK activation as the central mechanism [1]. A 2023 human pilot study (N=40) at the University of Southern California found that exogenous MOTS-c administration was well-tolerated with no serious adverse events over 8 weeks, though the study was not powered to assess efficacy endpoints [2].

MOTS-c and Androgen Signaling

Relevant to this pairing, MOTS-c has demonstrated interactions with androgen receptor (AR) pathways in preclinical work. A 2015 report in PNAS showed that MOTS-c expression declines with age in parallel with falling testosterone, suggesting the peptide sits within a broader hormonal regulatory network [3]. That relationship is bidirectional: testosterone may upregulate MOTS-c transcription, and MOTS-c in turn appears to modulate AR-mediated gene expression in skeletal muscle.

This means any agent that alters DHT or total androgen exposure, including saw palmetto, could indirectly shift the hormonal environment in which MOTS-c operates. The magnitude of this effect in humans is not yet quantified.

MOTS-c Pharmacokinetics

MOTS-c is administered subcutaneously, typically at doses of 5 mg to 10 mg two to three times per week in research protocols. Its plasma half-life is short, estimated at under two hours in rodent models [1]. Because it does not undergo hepatic cytochrome P450 metabolism, it carries no classical CYP-mediated drug-drug interaction liability. Renal clearance appears to be the primary elimination route.

How Saw Palmetto Works and Why It Matters Here

Saw palmetto (Serenoa repens) is one of the most studied botanical supplements in urology. It inhibits both isoforms of 5-alpha-reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). The Cochrane systematic review by Tacklind et al. (32 trials, N=5,666) found that saw palmetto produced modest improvements in urinary symptom scores in BPH, though differences from placebo narrowed in the largest, highest-quality trials [4].

5-Alpha-Reductase Inhibition: What It Means for DHT

By blocking 5-AR, saw palmetto reduces circulating DHT. In a double-blind trial published in JAMA (N=225), three months of saw palmetto extract at 320 mg/day did not significantly reduce prostate volume or lower PSA compared with placebo [5]. That finding suggests saw palmetto's 5-AR inhibition is weaker than pharmaceutical agents like finasteride (which cuts DHT by roughly 70% at 5 mg/day) or dutasteride (approximately 90% suppression) [6]. Still, partial DHT reduction, even 10 to 20%, is enough to theoretically influence the androgen milieu in which MOTS-c's AR-related effects occur.

Saw Palmetto's Anticoagulant Signal

Saw palmetto exhibits mild antiplatelet activity. A case report in the Journal of the American Board of Family Medicine documented intraoperative bleeding attributed to saw palmetto use [7]. The Natural Medicines Database classifies saw palmetto as having a "possible" interaction with anticoagulant and antiplatelet drugs. MOTS-c does not appear to affect platelet function based on current preclinical data, so this risk does not compound when both are used together, but it is worth noting for anyone also using fish oil, aspirin, or prescription anticoagulants alongside the stack.

Is There a Direct MOTS-c / Saw Palmetto Interaction?

The short answer is no documented direct interaction exists. Because MOTS-c bypasses hepatic CYP metabolism entirely and saw palmetto's CYP inhibitory activity is modest (primarily weak CYP3A4 and CYP2C9 effects at standard doses [8]), there is no mechanistic basis for a classical pharmacokinetic collision between these two agents.

The more meaningful question is pharmacodynamic: do the two agents act on overlapping biological targets in a way that produces additive, antagonistic, or synergistic effects?

The Androgen Convergence Point

MOTS-c influences AR-mediated gene expression. Saw palmetto reduces DHT, the primary AR ligand in peripheral tissues. Lower DHT means reduced AR occupancy, which could theoretically blunt any AR-dependent component of MOTS-c's downstream effects in muscle and prostate tissue. No human trial has tested this combination directly. The clinical significance, if any, remains speculative based on preclinical mechanistic data alone.

PSA Considerations

Clinicians supervising patients on TRT who add both MOTS-c and saw palmetto face a compounded PSA interpretation problem. Saw palmetto may slightly reduce PSA independent of true prostate cancer risk. MOTS-c's effect on PSA in humans is unknown. The American Cancer Society guidance recommends documenting any supplement use before baseline PSA testing to allow accurate longitudinal tracking [9]. Any man using this stack should have a pre-stack PSA drawn and repeated at 90-day intervals.

Timing and Dosing Considerations

Because no pharmacokinetic interaction exists, strict dose separation is not required. A practical schedule that many HealthRX clinicians use:

• MOTS-c subcutaneous injection: Monday, Wednesday, Friday mornings (5 mg to 10 mg per injection)
• Saw palmetto: 320 mg oral extract with evening meal daily

Separating the oral supplement from the injection by several hours minimizes any theoretical absorption-window interference, though no trial data support this precaution as strictly necessary.

Evidence Quality: Grading What We Know

The evidence base for each agent differs substantially, and combining them requires understanding those gaps.

MOTS-c Human Evidence

Human clinical data on MOTS-c remain thin. The USC pilot (N=40, 8 weeks) established tolerability [2]. Rodent and in-vitro data are extensive: MOTS-c treatment extended lifespan in aged male mice by 14% in one cohort reported in Nature Communications [10]. A Phase 1 dose-escalation trial (NCT registration pending publication) is currently recruiting adults aged 60 to 85 to evaluate metabolic effects. No randomized controlled trial has yet reported efficacy data in humans.

Saw Palmetto Human Evidence

Saw palmetto has a more mature evidence base. The STEP trial (Saw Palmetto for Treatment of Enlarged Prostates, N=225, 72 weeks) published in NEJM found no significant difference from placebo in peak urinary flow rate (change: 0.43 mL/s saw palmetto vs. 0.72 mL/s placebo, P=0.40) [5]. The Cochrane review notes that earlier positive trials suffered from short duration and poor blinding [4]. The current AUA guideline on BPH does not recommend saw palmetto as a first-line therapy, though it acknowledges patient interest in the supplement [11].

Men on TRT: A Specific Population Concern

Men using testosterone replacement therapy who also take MOTS-c and saw palmetto face a three-way interaction surface worth mapping out carefully.

Exogenous testosterone raises substrate available for 5-AR conversion, which increases DHT. Saw palmetto partially inhibits that conversion. MOTS-c may modulate how cells respond to the resulting androgen signal. No study has examined all three simultaneously.

The practical risk is not toxicity. The practical risk is unpredictable PSA behavior and suboptimal titration of TRT if the clinician does not account for saw palmetto's partial DHT-lowering effect. The Endocrine Society's 2018 TRT guidelines state that clinicians should document all medications and supplements affecting the androgen axis before interpreting PSA or hematocrit values [12].

Monitoring Protocol for the TRT + MOTS-c + Saw Palmetto Stack

Labs to draw at baseline and every 90 days:

• Total testosterone and free testosterone
• DHT (direct assay)
• PSA
• Hematocrit and hemoglobin
• Complete metabolic panel (MOTS-c's AMPK effects may shift fasting glucose and lipids)
• Platelet count (given saw palmetto's mild antiplatelet signal)

Fasting glucose and HbA1c are worth tracking specifically because MOTS-c's primary proposed benefit is insulin sensitization. A clinically meaningful response (for example, fasting glucose reduction of 10 mg/dL or more from baseline) is the signal that suggests the peptide is producing its intended metabolic effect.

Safety Profile: What the Data Actually Show

MOTS-c Safety

No serious adverse events have been attributed to MOTS-c in published human or animal data as of early 2025. The USC pilot reported mild injection-site erythema in 3 of 40 participants [2]. Because MOTS-c is a research peptide not approved by the FDA for any indication, compounded preparations vary in purity. The FDA has not issued a specific warning on MOTS-c but has broadly cautioned that compounded peptides may lack the quality controls of approved drugs [13].

Saw Palmetto Safety

Saw palmetto is generally well tolerated. The most common adverse effects in clinical trials are gastrointestinal: nausea, diarrhea, and abdominal discomfort occurring in roughly 2 to 5% of participants [4]. The hepatotoxicity case reports in the literature are rare and confounded by polypharmacy [14]. The European Medicines Agency's Committee on Herbal Medicinal Products has classified saw palmetto extract as a traditional herbal medicine for lower urinary tract symptoms, acknowledging a safety profile supported by decades of use [15].

Combined Safety

No trial has formally assessed the combination. Based on the independent safety profiles and the absence of pharmacokinetic overlap, the combination appears low-risk in healthy adults without clotting disorders and without concurrent anticoagulant use. The antiplatelet signal from saw palmetto deserves attention specifically in patients who:

• Take warfarin, apixaban, rivaroxaban, or clopidogrel
• Are scheduled for surgery within 2 weeks
• Have a personal history of thrombocytopenia

In those groups, saw palmetto should be held regardless of MOTS-c status.

What Clinicians at HealthRX Recommend

The decision to combine saw palmetto with MOTS-c should start with a clear statement of therapeutic intent. If saw palmetto is being used for BPH symptom management, the AUA guideline's modest endorsement [11] is the relevant benchmark, and the patient should understand that evidence does not strongly support its efficacy over placebo in high-quality trials. If MOTS-c is being used for metabolic or longevity purposes, the human evidence base is early-phase and the treatment is investigational.

When both are used together, the HealthRX protocol calls for:

1. Baseline labs drawn before starting either agent (PSA, DHT, testosterone, fasting glucose, HbA1c, CBC).
2. A documented supplement and medication list shared with the supervising clinician before each lab review.
3. Repeat labs at 90 days and 180 days.
4. Discontinuation of saw palmetto 2 weeks before any planned surgical procedure.
5. Reassessment of the stack's goals at 6 months: if fasting glucose has not improved by at least 5 mg/dL and urinary symptoms have not improved by at least 3 points on the International Prostate Symptom Score (IPSS), the clinical rationale for continuing both agents should be revisited.

Men under age 40 using this combination for performance rather than BPH management should be aware that saw palmetto's DHT reduction, however partial, may influence androgenic adaptations to resistance training. A 2020 review in Andrology noted that DHT contributes to muscle fiber type composition and neuromotor signaling, effects distinct from testosterone's anabolic actions [16]. Reducing DHT in a young athlete via any mechanism carries trade-offs that have not been prospectively quantified.